# A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

> **NCT05736419** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Sickle Cell Disease
- Thalassemia, Beta
- Thalassemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate Mofetil
- **BIOLOGICAL:** Rabbit ATG
- **DRUG:** Dexamethasone
- **DRUG:** Bortezomib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05736419
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-09
- **Primary completion:** 2027-02-09
- **Final completion:** 2027-02-09
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05736419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05736419, "A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05736419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*